Zobrazeno 1 - 10
of 137
pro vyhledávání: '"Masahiro Endo"'
Autor:
Taichi Miyawaki, Hirotsugu Kenmotsu, Kosei Doshita, Hiroaki Kodama, Naoya Nishioka, Yuko Iida, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1451-1460 (2023)
Abstract Background Programmed cell death 1 (PD‐1)/programmed cell death ligand (PD‐L1) inhibitors plus chemotherapy (ICI + Chemo) is the standard treatment for advanced non‐small‐cell lung cancer (NSCLC). However, the impact of tumour burden
Externí odkaz:
https://doaj.org/article/6a37993073c9463ea5acbdf407d85511
Autor:
Yoshinobu Saito, Masafumi Sata, Yoshihiko Ito, Takahiko Sakamoto, Yuichiro Ohe, Noriyo Yanagawa, Masahiko Kusumoto, Shinichi Sasaki, Tomohisa Baba, Tae Iwasawa, Kazuyoshi Kuwano, Hiroaki Sugiura, Yutaka Fujiwara, Masahiro Endo, Terufumi Kato, Junya Tominaga, Fumikazu Sakai, Katsunori Oikado, Hirotsugu Kenmotsu
Publikováno v:
Cancer Science
Nivolumab can cause interstitial lung disease (ILD), which may be fatal; however, mortality risk factors have not been identified. This postmarketing study evaluated the poor prognostic factors of ILD in nivolumab‐treated patients with non–small
Autor:
Yuichiro Ohe, Masafumi Sata, Kazuyoshi Kuwano, Yoshinobu Saito, Tomohisa Baba, Masahiko Kusumoto, Tae Iwasawa, Yoshihiko Ito, Takahiko Sakamoto, Yutaka Fujiwara, Terufumi Kato, Noriyo Yanagawa, Shinichi Sasaki, Junya Tominaga, Hirotsugu Kenmotsu, Masahiro Endo, Katsunori Oikado, Fumikazu Sakai, Hiroaki Sugiura
Publikováno v:
Cancer Science
Nivolumab, a human monoclonal antibody against programmed death‐1, is approved for the treatment of non–small cell lung cancer (NSCLC). Although nivolumab is generally well tolerated, it can cause interstitial lung disease (ILD), a rare but poten
Autor:
Michitoshi Yabe, Haruyasu Murakami, Takahisa Kawamura, Taichi Miyawaki, Tateaki Naito, Eriko Miyawaki, Toshiaki Takahashi, Hirotsugu Kenmotsu, Hideyuki Harada, Kazushige Wakuda, Naoya Nishioka, Akira Ono, Masahiro Endo, Nobuaki Mamesaya, Shota Omori, Haruki Kobayashi, Hiroaki Kodama, Yasuhiro Gon
Publikováno v:
Lung Cancer. 151:60-68
Objectives Pembrolizumab is recommended for patients with previously untreated non-small cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of ≥1%. The KEYNOTE-024 study described the efficacy of pembroli
Autor:
Yoshinobu Saito, Masahiko Kusumoto, Yuichiro Ohe, Masafumi Sata, Kei Sakamoto, Terufumi Kato, Toshimitsu Tokimoto, Reiko Tamura, Tomohisa Baba, Akihiko Gemma, Masatoshi Sugeno, Ou Yamaguchi, Wataru Shimizu, Masahiro Endo, Fumikazu Sakai
Publikováno v:
Japanese Journal of Clinical Oncology
Objective Adverse drug reactions (ADRs) during real-world osimertinib use were investigated in Japan. Methods Patients with epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer treated with second-line or later oral osime
Autor:
Tetsuya Mizuno, Mitsuhiro Isaka, Keiichi Ohshima, Haruki Kobayashi, Masatoshi Kusuhara, Hideaki Kojima, Kenichi Urakami, Yasuhisa Ohde, Tateaki Naito, Toshiaki Takahashi, Masakuni Serizawa, Ken Yamaguchi, Hayato Konno, Masahiro Endo, Takeshi Nagashima
Publikováno v:
Respirology (Carlton, Vic.)
Background and objective The efficacy expectation of immune checkpoint inhibitors against NSCLC in patients with ILD seems to be high because these populations are supposed to have high TMB. However, information about the characterization of TMB in p
Autor:
Naoya Nishioka, Eriko Miyawaki, Masahiro Endo, Shota Omori, Tateaki Naito, Kazuhisa Takahashi, Taichi Miyawaki, Haruki Kobayashi, Nobuaki Mamesaya, Haruyasu Murakami, Hideyuki Harada, Akira Ono, Ryo Ko, Hirotsugu Kenmotsu, Kazushige Wakuda, Toshiaki Takahashi, Keita Mori, Hiroaki Kodama
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Background Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI).
Autor:
Akira Ono, Hideyuki Harada, Haruyasu Murakami, Yasuhiro Gon, Kazushige Wakuda, Shota Omori, Tateaki Naito, Haruki Kobayashi, Masahiro Endo, Toshiaki Takahashi, Nobuaki Mamesaya, Hirotsugu Kenmotsu
Publikováno v:
Radiation Oncology (London, England)
Radiation Oncology, Vol 16, Iss 1, Pp 1-9 (2021)
Radiation Oncology, Vol 16, Iss 1, Pp 1-9 (2021)
Background Patients with lung cancer and interstitial lung disease treated with radiotherapy are at risk of developing radiation pneumonitis. However, the association between interstitial lung abnormalities (ILAs) and radiation pneumonitis in patient
Autor:
Yoko Nakasu, Eriko Miyawaki, Yasuhiro Gon, Toshiaki Takahashi, Shota Omori, Masahiro Endo, Hirotsugu Kenmotsu, Haruki Kobayashi, Akira Ono, Keita Mori, Takahisa Kawamura, Koichi Mitsuya, Haruyasu Murakami, Hideyuki Harada, Kazushige Wakuda, Kazuhisa Nakashima, Tateaki Naito, Nobuaki Mamesaya
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 104:604-613
Purpose It is unclear whether local therapy (LT) or epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) should take precedence for patients with EGFR-mutant non-small cell lung cancer (NSCLC) and brain metastases (BMs). The number
Autor:
Hirotsugu Kenmotsu, Haruyasu Murakami, Tateaki Naito, Takahisa Kawamura, Shota Omori, Keita Mori, Kazushige Wakuda, Haruki Kobayashi, Kazuhisa Nakashima, Akira Ono, Toshiaki Takahashi, Masahiro Endo
Publikováno v:
Investigational New Drugs
Summary 3rd-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, have reasonable efficacy in non–small-cell lung cancers (NSCLC) with EGFR mutations. However, the efficacy of osimertinib in NSCL